Oral mucositis is a complication of radiotherapy used for head-neck cancer treatment. Rosiglitazone protects normal tissues from radiation-induced oral mucositis. Rosiglitazone does not protect the tumor from therapeutic effect of irradiation. Rosiglitazone could be proposed as radioprotective agent in head-neck cancer.